Also our data indicate possible crosstalk between PI3K/Akt/mTOR and MAPK/ERK pathway, thus suggesting the potential of concomitant targeting of MAPK/ERK pathway to enhance antitumor effect of PI3K/mTOR dual inhibitors in cisplatin-resistant bladder cancer. The gene discussed is MTOR; the disease is urinary bladder cancer.